Seeking Alpha

Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
Seeking Alpha

Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Benzinga.com

Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?

On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...
Medscape

PREVAIL Yanked From ACC Program; Watchman Device Meets Safety End Point

(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...
Reuters

Boston Scientific says atrial fibrillation device in demand

(Reuters) - Boston Scientific Corp expects more hospitals will be able to offer its new atrial fibrillation treatment starting by the end of the third quarter as it paces the product's rollout to give ...